{"id":688522,"date":"2022-09-23T16:08:12","date_gmt":"2022-09-23T20:08:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/"},"modified":"2022-09-23T16:08:12","modified_gmt":"2022-09-23T20:08:12","slug":"adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","title":{"rendered":"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">REDWOOD CITY, Calif., Sept.  23, 2022  (GLOBE NEWSWIRE) &#8212; Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET.<\/p>\n<p>The on-demand webcast corporate presentation may be accessed under\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=khKQr_8I_Atz-FnvqE4PL7d_1bJWF9HgDSTC18TCa-Mf1HffenvO_KUeqWXrRky7bBhyB4wXJ1NbuC2yXHC63cIQ1Bc9mJHwTUQAga6t9eMQsPK2DVa8N5CB0uy7JbljO1NTX4CdhsZkVwYojJUDnadqRG772trQBY4YisYG9-U=\" rel=\"nofollow noopener\" target=\"_blank\">Events and Presentations<\/a>\u00a0in the Investors section of Adverum\u2019s website. A replay of the webcast will be available on the website for 90 days following the presentation.<\/p>\n<p>\n        <strong>About Adverum Biotechnologies<\/strong>\n      <\/p>\n<p>Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians\u2019 offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=56-9UCvvf4-LNFiklJKXJNYzc7mGl9cOih7dhjdT9T2zo5MBZTk8sg_nDlUzAecP1nCk3KkKGC6aCSNmEtgN7g==\" rel=\"nofollow noopener\" target=\"_blank\">www.adverum.com<\/a>.<\/p>\n<p>\n        <strong>Corporate &amp; Investor Inquiries<\/strong>\n      <\/p>\n<p>Anand Reddi<br \/>Vice President, Head of Corporate Strategy, External Affairs and Engagement<br \/>Adverum Biotechnologies, Inc.<br \/>T: 650-649-1358<br \/>E:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fZyg5zgDqilToK6XpSvMNsToKBlVywzV2kBlqA1x0rKpKSuosT8u3BLpMLtJCMbSFW-Dar9QIrj8DzXYStP8DBmBV7x5qfFXGS_DQT8pShk=\" rel=\"nofollow noopener\" target=\"_blank\">areddi@adverum.com<\/a><\/p>\n<p>\n        <strong>Media<\/strong>\n      <\/p>\n<p>Megan Talon<br \/>Associate Director, Corporate Communications<br \/>Adverum Biotechnologies, Inc.<br \/>T: 650-649-1006<br \/>E:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=faxjRQv4p39s_JTl5sEcZ6EPLfZxLSuI-XmKSW7wUpDerBIBidB9gnnXlXXN9QTvIjnVxKb2IWSxbZxzwYRfpRqKg9FHCvKDJ1SNJhEs9O8=\" rel=\"nofollow noopener\" target=\"_blank\">mtalon@adverum.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YjI1YWI0NjMtNzRjZS00NWZiLTllZGUtZGRjMTIwYmJmOWQyLTEwMTc3ODU=\/tiny\/Adverum-Biotechnologies-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET. The on-demand webcast corporate presentation may be accessed under\u00a0Events and Presentations\u00a0in the Investors section of Adverum\u2019s website. A replay of the webcast will be available on the website for 90 days following the presentation. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688522","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET. The on-demand webcast corporate presentation may be accessed under\u00a0Events and Presentations\u00a0in the Investors section of Adverum\u2019s website. A replay of the webcast will be available on the website for 90 days following the presentation. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care &hellip; Continue reading &quot;Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-23T20:08:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit\",\"datePublished\":\"2022-09-23T20:08:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\"},\"wordCount\":293,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\",\"name\":\"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=\",\"datePublished\":\"2022-09-23T20:08:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","og_locale":"en_US","og_type":"article","og_title":"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Peter Soparkar, chief operating officer of Adverum Biotechnologies, will present at the Jefferies Cell and Genetic Medicine Summit on September 29, 2022, at 9:30 a.m. ET. The on-demand webcast corporate presentation may be accessed under\u00a0Events and Presentations\u00a0in the Investors section of Adverum\u2019s website. A replay of the webcast will be available on the website for 90 days following the presentation. About Adverum Biotechnologies Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care &hellip; Continue reading \"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-23T20:08:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit","datePublished":"2022-09-23T20:08:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/"},"wordCount":293,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/","name":"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=","datePublished":"2022-09-23T20:08:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjUyNCM1MTY5NDM0IzIwMDYyMTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adverum-biotechnologies-to-participate-in-the-jefferies-cell-and-genetic-medicine-summit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adverum Biotechnologies to Participate in the Jefferies Cell and Genetic Medicine Summit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688522"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688522\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}